Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 8Esophageal Squamous Cell Carcinoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Rectal Neoplasms 2Intestinal Neoplasms 2Gastrointestinal Neoplasms 2Gastrointestinal Diseases 2Esophageal Neoplasms 2Digestive System Neoplasms 2Colonic Neoplasms 2Adenocarcinoma Of Esophagus 2Rectal Diseases 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Intestinal Diseases 1Digestive System Diseases 1Colonic Diseases 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Fluorouracil 12pembrolizumab 9Oxaliplatin 9Nivolumab 9Leucovorin 8Capecitabine 7Cisplatin 6Trastuzumab 4Paclitaxel 3Drug Therapy 3Docetaxel 3zimberelimab 2zanidatamab 2tucatinib 2spartalizumab 2durvalumab 2Radiotherapy 2Levoleucovorin 2Irinotecan 2Gemcitabine 2Carboplatin 2130-nm albumin-bound paclitaxel 2zolbetuximab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1toripalimab 1tislelizumab 1tezacitabine 1ribociclib 1quemliclustat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma Of Esophagus × Levoleucovorin × Clear all
NCT04210115 2026-05-13

KEYNOTE 975

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
703 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Taiho Oncology, Inc.

Phase 2 Active not recruiting
53 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡